Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Urinary Bladder Neoplasms 2Thrombocytopenia 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Lymphedema 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia 1Breast Neoplasms, Male 1Breast Neoplasms 1Blast Crisis 1Anemia, Refractory, with Excess of Blasts 1Anemia, Refractory 1

Interventions

Cytarabine 18fludarabine phosphate 17Cyclophosphamide 12Busulfan 11Filgrastim 10Peripheral Blood Stem Cell Transplantation 9Etoposide 9Azacitidine 9Methotrexate 8Decitabine 8Antilymphocyte Serum 8Specimen Handling 7Daunorubicin 7Biopsy 7fludarabine 6Tacrolimus 6Stem Cell Transplantation 6Cyclosporine 6decitabine and cedazuridine drug combination 5Melphalan 5Idarubicin 5Topotecan 4Rituximab 4Radiotherapy 4Prednisone 4Mitoxantrone 4Methylprednisolone 4Injections 4venetoclax 3sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myelodysplastic Syndromes × Vitamin E × Clear all
NCT00003619 2013-06-26

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, Anemia, Refractory, with Excess of Blasts, Blast Crisis, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocytopenia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡